SCHEMBL5116225

SCHEMBL5116225

CCc1cc2c(NCCc3ccc4c(c3)OCO4)nc(-n3cccn3)nc2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCDIN3D Q7Z5W3 1/20 0.44
PRKCI P41743 3/20 0.40
PDE5A O76074 1/20 0.39
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
FLT1 P17948 3/20 0.37
KDR P35968 3/20 0.37
NOS2 P35228 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
NOS1 P29475 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5123207 0.91 MAPT (0.43) PDE5AALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL5118165 0.90 BCDIN3D (0.45) BCDIN3DPDE5AADORA2AADORA1FLT1
SCHEMBL5122412 0.89 BCDIN3D (0.43) BCDIN3DPDE5AADORA2AADORA1FLT1
SCHEMBL5124576 0.88 FLT1 (0.41) BCDIN3DPDE5AADORA2AADORA1FLT1
SCHEMBL5116184 0.87 BCDIN3D (0.45) BCDIN3DPRKCIPDE5AADORA2AADORA1
SCHEMBL5129649 0.86 ICAM1 (0.40) PRKCIPDE5AALDH1A1CLK4KDM4E
SCHEMBL8206176 0.85 BCDIN3D (0.39) BCDIN3DPDE5ANOS2ALDH1A1CYP3A4
SCHEMBL5128257 0.85 NOS2 (0.52) BCDIN3DPDE5ANOS2NOS1
SCHEMBL5120681 0.85 BCDIN3D (0.40) BCDIN3DPDE5AADORA2AADORA1FLT1
SCHEMBL7619052 0.85 BCDIN3D (0.44) BCDIN3DPDE5AADORA2AADORA1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 BCDIN3D 1161/4885PRKCI 1513/4885PDE5A 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.